{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:29:54Z","timestamp":1792056594552,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10RR23057"],"award-info":[{"award-number":["1S10RR23057"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS100979"],"award-info":[{"award-number":["R01NS100979"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS110596"],"award-info":[{"award-number":["R01NS110596"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03NS114623"],"award-info":[{"award-number":["R03NS114623"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007857","name":"Intellectual and Developmental Disabilities Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018432","name":"California NanoSystems Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omtn.2022.04.012","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T01:54:09Z","timestamp":1651024449000},"page":"859-874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-9156","authenticated-orcid":false,"given":"Suhail","family":"Khoja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7439-3092","authenticated-orcid":false,"given":"Brian","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0465-8649","authenticated-orcid":false,"given":"Matthew","family":"Nitzahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8075-7278","authenticated-orcid":false,"given":"Jenna","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-8836","authenticated-orcid":false,"given":"Adam","family":"Eliav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eram","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-2149","authenticated-orcid":false,"given":"Emma","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-3921","authenticated-orcid":false,"given":"Kristine E.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo G.V.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhak","family":"Nissim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1863-6600","authenticated-orcid":false,"given":"Stephen D.","family":"Cederbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-6776","authenticated-orcid":false,"given":"Gerald S.","family":"Lipshutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2022.04.012_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"1909","article-title":"The metabolic and molecular bases of inherited disease","author":"Brusilow","year":"2001"},{"key":"10.1016\/j.omtn.2022.04.012_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/gt.2012.99","article-title":"AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse","volume":"20","author":"Lee","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib3","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/mt.2012.129","article-title":"Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy","volume":"20","author":"Lee","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.gene.2012.08.003","article-title":"Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes","volume":"509","author":"Carvalho","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.omtn.2022.04.012_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10545-009-1148-2","article-title":"Long-term neurodevelopmental effects of early detection and treatment in a 6-year-old patient with argininaemia diagnosed by newborn screening","volume":"32","author":"Edwards","year":"2009","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2022.04.012_bib6","first-page":"1281","article-title":"Molecular genetic study of human arginase deficiency","volume":"50","author":"Grody","year":"1992","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2022.04.012_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.06.025","article-title":"Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?","volume":"104","author":"Jain-Ghai","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtn.2022.04.012_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pediatrneurol.2010.11.003","article-title":"Argininemia presenting with progressive spastic diplegia","volume":"44","author":"Lee","year":"2011","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtn.2022.04.012_bib9","first-page":"1406","article-title":"Three novel mutations in the liver-type arginase gene in three unrelated Japanese patients with argininemia","volume":"51","author":"Uchino","year":"1992","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2022.04.012_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00210403","article-title":"Molecular basis of phenotypic variation in patients with argininemia","volume":"96","author":"Uchino","year":"1995","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2022.04.012_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/humu.1380040210","article-title":"Identification of mutations (D128G, H141L) in the liver arginase gene of patients with hyperargininemia","volume":"4","author":"Vockley","year":"1994","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.04.012_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mpd.2003.97","article-title":"Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema","volume":"142","author":"Picker","year":"2003","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtn.2022.04.012_bib13","series-title":"GeneReviews((R))","article-title":"Urea cycle disorders overview","author":"Ah Mew","year":"1993"},{"key":"10.1016\/j.omtn.2022.04.012_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pediatrneurol.2012.03.016","article-title":"Clinical features and neurologic progression of hyperargininemia","volume":"46","author":"Carvalho","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtn.2022.04.012_bib15","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A."},{"key":"10.1016\/j.omtn.2022.04.012_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1023\/A:1005313809037","article-title":"The human arginases and arginase deficiency","volume":"21","author":"Iyer","year":"1998","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2022.04.012_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/088307389701200502","article-title":"Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy: case reports and literature review","volume":"12","author":"Prasad","year":"1997","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.omtn.2022.04.012_bib18","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1523\/JNEUROSCI.0897-16.2016","article-title":"Rescue of the functional alterations of motor cortical circuits in arginase deficiency by neonatal gene therapy","volume":"36","author":"Cantero","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2022.04.012_bib19","doi-asserted-by":"crossref","first-page":"e130260","DOI":"10.1172\/jci.insight.130260","article-title":"Hepatic arginase deficiency fosters dysmyelination during postnatal CNS development","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2022.04.012_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pediatrneurol.2009.07.017","article-title":"Diffusion tensor imaging in arginase deficiency reveals damage to corticospinal tracts","volume":"42","author":"Oldham","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtn.2022.04.012_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.braindev.2010.03.001","article-title":"A long-term survival case of arginase deficiency with severe multicystic white matter and compound mutations","volume":"33","author":"Segawa","year":"2011","journal-title":"Brain Dev."},{"key":"10.1016\/j.omtn.2022.04.012_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1552-6569.2007.00217.x","article-title":"Neuroimaging findings in hyperargininemia","volume":"18","author":"Gungor","year":"2008","journal-title":"J.\u00a0Neuroimaging"},{"key":"10.1016\/j.omtn.2022.04.012_bib23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib24","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2022.04.012_bib25","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/mt.2009.65","article-title":"Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector","volume":"17","author":"Gau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/dmcn.12488","article-title":"Treatment of arginase deficiency revisited: guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring","volume":"56","author":"Amayreh","year":"2014","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omtn.2022.04.012_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijdevneu.2010.06.008","article-title":"Guanidino compounds inhibit acetylcholinesterase and butyrylcholinesterase activities: effect neuroprotector of vitamins E plus C","volume":"28","author":"Delwing-de Lima","year":"2010","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.omtn.2022.04.012_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0033-1360479","article-title":"Epilepsia partialis continua and generalized nonconvulsive status epilepticus during the course of argininemia: a\u00a0report on two cases","volume":"45","author":"Grioni","year":"2013","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.omtn.2022.04.012_bib29","first-page":"25","article-title":"Liver transplantation prevents progressive neurological impairment in argininemia","volume":"11","author":"Silva","year":"2013","journal-title":"JIMD Rep."},{"key":"10.1016\/j.omtn.2022.04.012_bib30","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1128\/MCB.22.13.4491-4498.2002","article-title":"Mouse model for human arginase deficiency","volume":"22","author":"Iyer","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2022.04.012_bib31","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ymgme.2010.01.012","article-title":"Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia","volume":"100","author":"Deignan","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtn.2022.04.012_bib32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2007.09.016","article-title":"Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia","volume":"93","author":"Deignan","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtn.2022.04.012_bib33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nn738","article-title":"TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination","volume":"4","author":"Arnett","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtn.2022.04.012_bib34","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1523\/JNEUROSCI.0444-06.2006","article-title":"1-Integrin signaling mediates premyelinating oligodendrocyte survival but is not required for CNS myelination and remyelination","volume":"26","author":"Benninger","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2022.04.012_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.0305-1846.2001.00301.x","article-title":"Episodic demyelination and subsequent remyelination within the murine central nervous system: changes in axonal calibre","volume":"27","author":"Mason","year":"2001","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtn.2022.04.012_bib36","doi-asserted-by":"crossref","first-page":"e7754","DOI":"10.1371\/journal.pone.0007754","article-title":"What is the optimal value of the g-ratio for myelinated fibers in the rat CNS? A theoretical approach","volume":"4","author":"Chomiak","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2022.04.012_bib37","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib38","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","article-title":"A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s12272-014-0498-y","article-title":"Purification and immobilization of L-arginase from thermotolerant Penicillium chrysogenum KJ185377.1; with unique kinetic properties as thermostable anticancer enzyme","author":"El-Sayed","year":"2014","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.omtn.2022.04.012_bib40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.addr.2020.04.002","article-title":"Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes","volume":"159","author":"Veiga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2022.04.012_bib41","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0021-9258(19)85022-6","article-title":"Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes","volume":"264","author":"Bisgaier","year":"1989","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2022.04.012_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbrc.2004.12.137","article-title":"The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse","volume":"328","author":"Yan","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2022.04.012_bib43","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/mt.2014.99","article-title":"Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice","volume":"22","author":"Hu","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ymgme.2013.06.020","article-title":"Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse","volume":"110","author":"Kasten","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtn.2022.04.012_bib45","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2022.04.012_bib46","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ymthe.2020.04.011","article-title":"Split AAV-mediated gene therapy restores ureagenesis in a murine model of carbamoyl phosphate synthetase 1 deficiency","volume":"28","author":"Nitzahn","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.012_bib47","doi-asserted-by":"crossref","first-page":"9710","DOI":"10.1074\/jbc.M113.544726","article-title":"The molecular and metabolic influence of long term agmatine\u00a0consumption","volume":"289","author":"Nissim","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2022.04.012_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ymgme.2018.04.001","article-title":"Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy","volume":"124","author":"Khoja","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtn.2022.04.012_bib49","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1523\/JNEUROSCI.1770-16.2016","article-title":"Conditional deletion of the L-type calcium channel Cav1.2 in oligodendrocyte progenitor cells affects postnatal myelination in mice","volume":"36","author":"Cheli","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.omtn.2022.04.012_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/2051-5960-2-42","article-title":"Optimization of electron microscopy for human brains with long-term fixation and fixed-frozen sections","volume":"2","author":"Liu","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtn.2022.04.012_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/pr.2015.109","article-title":"Augmentation of transgene-encoded protein after neonatal injection of adeno-associated virus improves hepatic copy number without immune responses","volume":"78","author":"Tai","year":"2015","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.omtn.2022.04.012_bib52","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jgm.1496","article-title":"RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy","volume":"12","author":"Hu","year":"2010","journal-title":"J.\u00a0Gene Med."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:29:30Z","timestamp":1761874170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253122000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":52,"alternative-id":["S2162253122000889"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2022.04.012","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2022.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}